Evaluation of Minimal Residual Disease in Patients with Neuroblastoma

Abstract excerpt

Neuroblastoma (NB) is a pediatric extracranial solid tumor that accounts for approximately 15% of all pediatric cancer deaths. More than 50% of patients with newly diagnosed NB are classified into a high-risk group with an approximately 50% long-term survival rate. Although most high-risk patients with NB achieve remission, more than half may have minimal residual disease (MRD) that eventually causes relapse....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Neuroblastoma Research and Treatments
• Share to Virus-based gene therapy research